| Identification | |
| Name: | Repaglinide |
| Synonyms: | (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid;Novonorm;Prandin; |
| CAS: | 135062-02-1 |
| Molecular Formula: | C27H36N2O4 |
| Molecular Weight: | 452.58574 |
| InChI: | InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1 |
| Molecular Structure: | ![(C27H36N2O4) (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid;Novo...](https://img.guidechem.com/casimg/135062-02-1.gif) |
| Properties | |
| Density: | 1.137 g/cm3 |
| Water Solubility: | DMSO: 34 mg/mL |
| Solubility: | DMSO: 34 mg/mL |
| Appearance: | White to Off-White Solid |
| Specification: |
?Repaglinide (CAS NO.135062-02-1) should not be administered concomitantly with gemfibrozil, clarithromycin or azole antifungals such as itraconazole or ketoconazole.Administration of both repaglinide and one or more of these drugs results in an increase in plasma concentration of repaglinide and may lead to hypoglycemia. |
| Biological Activity: | K ATP channel blocker that binds with high affinity for SUR1 when co-expressed with Kir6.2 (K d = 0.42 nM). Antidiabetic glucose regulator with hypoglycaemic effect in vivo . |
| Color: | white |
| Usage: | Non-sulfonylurea oral hypoglycemic agent. Used as an antidiabetic |
| Safety Data | |
 |
|
